🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Edmonton
Clinical trial register · Canada

Clinical Trials in Edmonton, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Canada and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 6540 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:55 UTC
6540
Studies in scope
all four open statuses
3515
Recruiting now
open to new participants
887
Lead sponsors
across recruiting studies
Top sites
Toronto 68 Vancouver 36 Halifax 28 Edmonton 27 Hamilton 27
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
University of Alberta176 AstraZeneca52 AbbVie39 National Cancer Institute (NCI)27 Merck Sharp & Dohme LLC24 Clear sponsor filter
Site location
Toronto68 Vancouver36 Halifax28 Edmonton27 Hamilton27
All 35 locations
Target enrolment
to

Trials with a site in Edmonton

27 of 6540 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Canada
Start
Recruiting
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
NCT06124157B Acute Lymphoblastic Leukemia
DrugsCalaspargase Pegol·Thioguanine·Oncaspar·PEG-Asparaginase
National Cancer Institute (NCI)
Phase 2
222
Calgary, Edmonton, Vancouver, Winnipeg, Halifax, Hamilton, Toronto, Montreal
2025-05-30
Recruiting
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
NCT05554406Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related
DrugsLiposome-encapsulated Daunorubicin-Cytarabine·Daunorubicin·Cytarabine·Azacitidine
National Cancer Institute (NCI)
Phase 2
335
Calgary, Edmonton, Winnipeg, Halifax, Ottawa, Toronto, Greenfield Park, Montreal
2024-09-25
Recruiting
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
NCT05554393Acute Myeloid Leukemia
DrugsDaunorubicin·Cytarabine·Azacitidine·Venetoclax
National Cancer Institute (NCI)
Phase 2
153
Calgary, Edmonton, Winnipeg, Halifax, Hamilton, Toronto, Greenfield Park, Montreal
2024-09-13
Recruiting
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
NCT06422806Metastatic Dedifferentiated Liposarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8
DrugsDoxorubicin·Keytruda·Pembrolizumab
National Cancer Institute (NCI)
Phase 3
365
Calgary, Edmonton, Vancouver, Winnipeg, Hamilton, Ottawa, Toronto, Québec
2024-09-11
Recruiting
A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
NCT06064097Stage II Nasopharyngeal Carcinoma AJCC v8, Stage III Nasopharyngeal Carcinoma AJCC v8, Stage IV Nasopharyngeal Carcinoma AJCC v8
DrugsCDDP·Nivolumab·Gemcitabine·Cisplatin
National Cancer Institute (NCI)
Phase 2
50
Calgary, Edmonton, Toronto, Montreal, Sherbrooke
2024-06-25
Recruiting
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
NCT05564390Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related
DrugsEmavusertib·Olutasidenib·Mylotarg·Liposome-encapsulated Daunorubicin-Cytarabine
National Cancer Institute (NCI)
Phase 2
2,000
Calgary, Edmonton, Winnipeg, Halifax, Hamilton, Ottawa, Toronto, Greenfield Park
2024-06-18
Recruiting
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
NCT06172296Ganglioneuroblastoma, Nodular, Neuroblastoma
DrugsDinutuximab·Isotretinoin·CDDP·Doxorubicin
National Cancer Institute (NCI)
Phase 3
478
Calgary, Edmonton, Vancouver, Winnipeg, St. John's, Halifax, Hamilton, London
2024-04-19
Recruiting
A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis
NCT05828069Recurrent Langerhans Cell Histiocytosis, Refractory Langerhans Cell Histiocytosis
DrugTovorafenib
National Cancer Institute (NCI)
Phase 2
48
Edmonton, Vancouver, Halifax, Hamilton, London, Toronto, Montreal, Sherbrooke
2024-03-28
Recruiting
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
NCT05987241Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma, Muscle Invasive Ureter Urothelial Carcinoma, Muscle Invasive Urethral Urothelial Carcinoma
DrugsRelatlimab·Nivolumab
National Cancer Institute (NCI)
Phase 2/3
992
Calgary, Edmonton, Vancouver, Kitchener, London, Ottawa, Toronto, Regina
2024-02-02
Recruiting
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
NCT05675410Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
DrugsBleomycin·Brentuximab Vedotin·Dacarbazine·Doxorubicin Hydrochloride
National Cancer Institute (NCI)
Phase 3
1,875
Calgary, Edmonton, Vancouver, Winnipeg, Halifax, Hamilton, London, Ottawa
2023-05-11
Active, closed
Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study
NCT05092958Advanced Bladder Urothelial Carcinoma, Advanced Renal Pelvis Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma, Advanced Urethral Urothelial Carcinoma
DrugsCabozantinib S-malate·Avelumab·Cabozantinib
National Cancer Institute (NCI)
Phase 3
654
Edmonton, Toronto, Regina, Saskatoon
2022-06-03
Recruiting
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
NCT05099003Malignant Glioma
DrugSelinexor
National Cancer Institute (NCI)
Phase 1/2
132
Edmonton, Vancouver, Winnipeg, Halifax, Hamilton, Toronto, Montreal, Sherbrooke
2022-05-31
Active, closed
Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
NCT04759586Primary Mediastinal Large B-Cell Lymphoma
DrugsFilgrastim·Pegfilgrastim·Doxorubicin Hydrochloride·Adriamycin
National Cancer Institute (NCI)
Phase 3
244
Edmonton, Winnipeg, St. John's, Halifax, Hamilton, London, Ottawa, Toronto
2021-10-05
Active, closed
A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma
NCT04576117Recurrent Low Grade Astrocytoma, Recurrent WHO Grade 2 Glioma, Refractory Low Grade Astrocytoma, Refractory Low Grade Glioma
DrugsVinblastine Sulfate·Selumetinib
National Cancer Institute (NCI)
Phase 3
300
Edmonton, Vancouver, Winnipeg, Halifax, Ottawa, Toronto, Montreal, Sherbrooke
2021-02-16
Recruiting
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
NCT04546399Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia
DrugsHydrocortisone Sodium Succinate·Enrylaze·Asparaginase Erwinia chrysanthemi·Calaspargase Pegol
National Cancer Institute (NCI)
Phase 2
461
Calgary, Edmonton, Vancouver, Winnipeg, St. John's, Halifax, Montreal, Sherbrooke
2020-12-17
Active, closed
A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia
NCT03914625B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Down Syndrome
DrugsEnrylaze·Asparaginase Erwinia chrysanthemi·Erwinase·Lederfolin
National Cancer Institute (NCI)
Phase 3
6,720
Calgary, Edmonton, Vancouver, Winnipeg, St. John's, Halifax, Hamilton, Kingston
2019-07-03
Active, closed
Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer
NCT03793179Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
DrugsPemetrexed·Keytruda·Carboplatin·Pembrolizumab
National Cancer Institute (NCI)
Phase 3
600
Calgary, Edmonton, Surrey, Vancouver, Saint John, Kingston, Saint Catharines, Thunder Bay
2019-04-05
Active, closed
Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy
NCT03055013Metastatic Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage II Renal Cell Cancer AJCC v7, Stage III Renal Cell Cancer AJCC v7
DrugsOpdivo·Nivolumab
National Cancer Institute (NCI)
Phase 3
819
Calgary, Edmonton, Winnipeg, Moncton, Halifax, Hamilton, Kingston, London
2017-04-28
Active, closed
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
NCT02954874Breast Carcinoma In Situ, Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7
DrugsKeytruda·Pembrolizumab
National Cancer Institute (NCI)
Phase 3
1,195
Calgary, Edmonton, Surrey, Vancouver, Moncton, Saint John, St. John's, Hamilton
2017-01-18
Active, closed
Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
NCT02567435Alveolar Rhabdomyosarcoma, Botryoid-Type Embryonal Rhabdomyosarcoma, Embryonal Rhabdomyosarcoma, Rhabdomyosarcoma
DrugsTemsirolimus·Dactinomycin·Vinorelbine·Vincristine
National Cancer Institute (NCI)
Phase 3
325
Calgary, Edmonton, Vancouver, Winnipeg, St. John's, Halifax, Hamilton, Kingston
2016-06-01
Active, closed
Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer
NCT02502266Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma
DrugsCediranib Maleate·Pegylated liposomal doxorubicin·Topotecan·Olaparib
National Cancer Institute (NCI)
Phase 2/3
582
Calgary, Edmonton, Barrie, Hamilton, Kingston, London, Sault Ste. Marie, Toronto
2016-05-03
Active, closed
Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02446600Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Ovarian Clear Cell Adenocarcinoma
DrugsCediranib Maleate·Pegylated liposomal doxorubicin·Olaparib·Gemcitabine
National Cancer Institute (NCI)
Phase 3
579
Calgary, Edmonton, Hamilton, London, Ottawa, Sault Ste. Marie, Toronto, Montreal
2016-03-28
Active, closed
Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma
NCT02166463Ann Arbor Stage IIB Hodgkin Lymphoma, Ann Arbor Stage IIIB Hodgkin Lymphoma, Ann Arbor Stage IVA Hodgkin Lymphoma, Ann Arbor Stage IVB Hodgkin Lymphoma
DrugsBleomycin·Brentuximab Vedotin·Doxorubicin Hydrochloride·Adriamycin
National Cancer Institute (NCI)
Phase 3
600
Calgary, Edmonton, Vancouver, Winnipeg, Halifax, Hamilton, Kingston, London
2015-03-19
Active, closed
Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma
NCT02306161Metastatic Ewing Sarcoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Bone Marrow, Metastatic Malignant Neoplasm in the Lung
DrugsVincrystine·Ifosfamide·Doxorubicin Hydrochloride·Adriamycin
National Cancer Institute (NCI)
Phase 3
312
Calgary, Edmonton, Vancouver, Winnipeg, St. John's, Halifax, Hamilton, Kingston
2014-12-12
Active, closed
Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
NCT02112916Adult T Acute Lymphoblastic Leukemia, Ann Arbor Stage II Adult Lymphoblastic Lymphoma, Ann Arbor Stage II Childhood Lymphoblastic Lymphoma, Ann Arbor Stage III Adult Lymphoblastic Lymphoma
DrugsDoxorubicin Hydrochloride·Adriamycin·Daunorubicin·Bortezomib
National Cancer Institute (NCI)
Phase 3
847
Calgary, Edmonton, Vancouver, Winnipeg, St. John's, Halifax, Hamilton, Kingston
2014-10-04
Active, closed
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
NCT01274338Melanoma of Unknown Primary, Recurrent Melanoma, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7
DrugsBioferon·Ipilimumab
National Cancer Institute (NCI)
Phase 3
1,673
Edmonton, Winnipeg, Greater Sudbury, Kitchener, Ottawa, Toronto, Montreal
2011-06-17
Active, closed
Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia
NCT00070499Chronic Myeloid Leukemia, BCR-ABL1 Positive
DrugsDasatinib·Imatinib
National Cancer Institute (NCI)
Phase 2
406
Edmonton, Winnipeg, Moncton, St. John's, Halifax, Hamilton, London, Toronto
2004-08-15
Rows per page Showing 1–27 of 27
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Canadian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 30 September 2026. https://priyalifescience.com/clinical-trials-canada/city/edmonton

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Canada and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 6,540 studies in total at the last sync on 26 Sep 2026, 19:55 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 27 of those studies with a site in Edmonton that also match the filters currently applied.

How many clinical trials are recruiting in Edmonton?

12 of the 27 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:55 UTC sync. A further 0 have not yet opened recruitment, 15 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Edmonton), 27 studies
PhaseStudiesRecruitingShare
Phase 316359.3%
Phase 28729.6%
Phase 2/3217.4%
Phase 1/2113.7%

Most active sponsors

Lead sponsors with the most studies (Edmonton)
Lead sponsorStudiesRecruiting
National Cancer Institute (NCI)2712
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.